Previous close | 221.50 |
Open | 225.50 |
Bid | 226.02 x 900 |
Ask | 226.36 x 900 |
Day's range | 217.87 - 233.30 |
52-week range | 6.77 - 331.68 |
Volume | 1,015,876 |
Avg. volume | 5,042,652 |
Market cap | 15.366B |
Beta (5Y monthly) | 1.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Johnson & Johnson and Novavax are approaching the finish line in this race. A U.S. Food and Drug Administration (FDA) committee meets today, Feb. 26, to discuss a possible Emergency Use Authorization (EUA) for the Johnson & Johnson candidate. A trial report released this week shows Johnson & Johnson's investigational vaccine fulfilled (and exceeded) efficacy and safety requirements.
Novavax (NASDAQ: NVAX) is one stock that I made the right call on; it's been a huge winner. As far back as March 2018, I wrote that "if you're willing to take on risk, buying a small position in Novavax could pay off in a big way." Throughout 2020, I sang Novavax's praises.
Novavax doesn't have products on the market yet, which means the biotech company is yet to report an annual profit. Novavax recently reported U.K. phase 3 trial results and just completed enrollment in a U.S. phase 3 trial. Possible regulatory authorizations sit on the horizon.